By modulating key pathological mechanisms of psoriasis, including the downregulation of HIF-1α and the restoration of p53 expression, SHTLS appears to significantly impact the crosstalk between these two critical markers, thereby contributing to its therapeutic potential in psoriatic lesions (Figure 6C–E). This evidence concerns the gene TP53 and psoriasis.